XTX Topco Ltd Takes $1.97 Million Position in Amedisys, Inc. (NASDAQ:AMED)

XTX Topco Ltd purchased a new position in Amedisys, Inc. (NASDAQ:AMED - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 21,697 shares of the health services provider's stock, valued at approximately $1,970,000. XTX Topco Ltd owned approximately 0.07% of Amedisys at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Blue Trust Inc. grew its position in Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after acquiring an additional 124 shares in the last quarter. HBW Advisory Services LLC purchased a new position in shares of Amedisys in the 4th quarter worth about $38,000. Versant Capital Management Inc increased its position in shares of Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock valued at $41,000 after purchasing an additional 183 shares during the last quarter. Vestcor Inc purchased a new position in shares of Amedisys during the 4th quarter valued at about $73,000. Finally, Venturi Wealth Management LLC lifted its position in Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock worth $89,000 after buying an additional 779 shares during the last quarter. Institutional investors own 94.36% of the company's stock.

Amedisys Trading Down 0.2 %

Shares of NASDAQ:AMED traded down $0.15 during trading on Friday, reaching $91.76. 133,860 shares of the company traded hands, compared to its average volume of 400,335. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of 36.41, a P/E/G ratio of 1.78 and a beta of 0.89. The business's fifty day moving average is $92.14 and its 200-day moving average is $91.91.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $598.05 million for the quarter, compared to analysts' expectations of $602.38 million. As a group, analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on AMED. Royal Bank of Canada reiterated an "outperform" rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday. Stephens reiterated an "equal weight" rating and issued a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $100.75.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.